155 Participants Needed

Therapeutic Evaluative Conditioning for Suicidal Thoughts and Behaviors

(TEC Trial)

JO
KZ
Overseen ByKelly Zuromski, PhD
Age: < 65
Sex: Any
Trial Phase: Academic
Sponsor: Franciscan Hospital For Children, INC.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Therapeutic Evaluative Conditioning for reducing suicidal thoughts and behaviors?

Preliminary studies have shown that Therapeutic Evaluative Conditioning (TEC), a scalable app-based treatment, can reduce self-injurious behaviors, including suicidal actions. This suggests that TEC might be effective in addressing suicidal thoughts and behaviors.12345

How is the treatment Therapeutic Evaluative Conditioning (TEC) different from other treatments for suicidal thoughts and behaviors?

Therapeutic Evaluative Conditioning (TEC) is unique because it is a scalable, app-based treatment that can be self-administered, making it more accessible than traditional therapies. Unlike other treatments, TEC focuses on reducing self-injurious behaviors through a mobile platform, which allows for widespread use and integration into traditional clinical settings.12678

What is the purpose of this trial?

Suicide is the 2nd leading cause of death among adolescents, with the highest risk period for suicide being the month following psychiatric inpatient hospitalization. The investigators propose testing a brief, scalable intervention using evaluative conditioning aimed at reducing suicidal thoughts and behaviors among adolescents during and after inpatient hospitalization. Scalable interventions, such as the one proposed that reduce suicide risk during this markedly high-risk period, could result in large-scale decreases in suicide death.

Research Team

AM

Alexander Millner, PhD

Principal Investigator

Principal Investigator

Eligibility Criteria

This trial is for adolescents aged 12-19 who are patients at the McLean-Franciscan Child and Adolescent Inpatient Program, have experienced self-harm or suicidal thoughts, can assent to participate, own a smartphone, and have parental permission. It excludes those heading to long-term residential care post-discharge or with cognitive impairments that prevent full participation.

Inclusion Criteria

Be a patient on McLean-Franciscan Child and Adolescent Inpatient Program (MF-CAIP) of Franciscan Children's (FC)
I have been to the hospital for self-harm, thoughts of suicide, or a suicide attempt.
Have a parent/guardian that can provide permission
See 3 more

Exclusion Criteria

Any factor that impairs an individual's ability to comprehend and effectively participate in the study, including inability to speak or write English fluently
I expect to be discharged to a residential program where I'll stay for more than 14 days.
Presence of gross cognitive impairment due to florid psychosis, intellectual disability, dementia, acute intoxication, etc., or the presence of extremely agitated or violent behavior

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Inpatient period

Baseline data collection, TEC intervention initiation, and assessment of treatment targets and outcomes

2 weeks
Daily sessions (in-person)

Post-discharge intervention period

Daily TEC intervention and assessments via smartphone app

4 weeks
Remote monitoring

Post-intervention follow-up

Assessment of treatment effects persistence without intervention

4 weeks
Remote assessments

Treatment Details

Interventions

  • Neutral comparison condition
  • Therapeutic Evaluative Conditioning
Trial Overview The study tests a brief intervention called Therapeutic Evaluative Conditioning against a neutral condition to reduce suicidal thoughts and behaviors in hospitalized adolescents. The goal is to find an easily scalable method that could significantly lower suicide risks during the critical period after hospitalization.
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: Active intervention armActive Control1 Intervention
Participants will complete the intervention on a mobile device.
Group II: Control armPlacebo Group1 Intervention
Participants will complete the sham comparator on a mobile device.

Therapeutic Evaluative Conditioning is already approved in United States for the following indications:

🇺🇸
Approved in United States as Therapeutic Evaluative Conditioning for:
  • Suicidal thoughts and behaviors in adolescents during and after psychiatric inpatient hospitalization

Find a Clinic Near You

Who Is Running the Clinical Trial?

Franciscan Hospital For Children, INC.

Lead Sponsor

Trials
2
Recruited
230+

Harvard University

Collaborator

Trials
237
Recruited
588,000+

National Institute of Mental Health (NIMH)

Collaborator

Trials
3,007
Recruited
2,852,000+

Findings from Research

Electroconvulsive therapy (ECT) is a rapid and effective treatment for severe depression, capable of quickly reducing or eliminating suicidal thoughts and behaviors, as demonstrated in a case study of an 88-year-old man who showed significant improvement after just one session.
The patient remained free of suicidal ideation for 5 months following the treatment, highlighting the potential long-term benefits of ECT even with a minimal number of sessions.
Resolution of severe suicidality with a single electroconvulsive therapy.Kobeissi, J., Aloysi, A., Tobias, K., et al.[2011]
The app-based treatment called Therapeutic Evaluative Conditioning (TEC) has shown promise in reducing self-injurious behaviors (SIBs) in preliminary studies, addressing a significant public health issue.
A case illustration of a young adult female with a history of SIBs suggests that TEC can be effectively implemented in traditional clinical settings, potentially enhancing treatment options for individuals with limited success from previous interventions.
How to Implement Therapeutic Evaluative Conditioning in a Clinical Setting.Franklin, JC., Fox, KR., Ribeiro, JD.[2019]
In a study of 14,810 patients who received electroconvulsive therapy (ECT) and 58,369 matched controls, ECT did not significantly reduce the short-term risk of suicide compared to other mental health treatments, indicating that its effectiveness in this regard is inconclusive.
Despite ECT being effective in reducing suicidal ideation, the study found that patients who received ECT remained at a high risk for suicide, suggesting that additional interventions may be necessary to address this risk.
Effects of Electroconvulsive Therapy on Short-Term Suicide Mortality in a Risk-Matched Patient Population.Peltzman, T., Shiner, B., Watts, BV.[2022]

References

Resolution of severe suicidality with a single electroconvulsive therapy. [2011]
How to Implement Therapeutic Evaluative Conditioning in a Clinical Setting. [2019]
Effects of Electroconvulsive Therapy on Short-Term Suicide Mortality in a Risk-Matched Patient Population. [2022]
Response of energy and suicidal ideation to ECT. [2007]
Superior anti-suicidal effects of electroconvulsive therapy in unipolar disorder and bipolar depression. [2019]
Understanding the context of novel interventions for self-injurious thoughts and behaviors: A reply to Nielsen et al. [2019]
"Great powers and great responsibilities": A brief comment on "A brief mobile app reduces nonsuicidal and suicidal self-injury: Evidence from three randomized controlled trials" (Franklin et al., 2016). [2019]
Effects of Electroconvulsive Therapy on Suicidal Behavior and Emergency Department Use Among Homeless Veterans: A Propensity Score-Matched Study. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security